CN111217760B - 一种磺胺氯吡嗪钠的合成方法 - Google Patents
一种磺胺氯吡嗪钠的合成方法 Download PDFInfo
- Publication number
- CN111217760B CN111217760B CN202010230529.8A CN202010230529A CN111217760B CN 111217760 B CN111217760 B CN 111217760B CN 202010230529 A CN202010230529 A CN 202010230529A CN 111217760 B CN111217760 B CN 111217760B
- Authority
- CN
- China
- Prior art keywords
- sodium
- sulfachloropyrazine
- acid
- synthesizing
- reaction kettle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 30
- 239000011734 sodium Substances 0.000 title claims abstract description 30
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 29
- QKLPUVXBJHRFQZ-UHFFFAOYSA-N 4-amino-n-(6-chloropyrazin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=CC(Cl)=N1 QKLPUVXBJHRFQZ-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000010189 synthetic method Methods 0.000 title description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 60
- NIUFFODHMKLSCH-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-chloropyrazin-2-yl)azanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=CN=CC(Cl)=N1 NIUFFODHMKLSCH-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000002253 acid Substances 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 239000011230 binding agent Substances 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims abstract description 14
- JTPXVCKCLBROOJ-UHFFFAOYSA-N 2-amino-6-chloropyrazine Chemical compound NC1=CN=CC(Cl)=N1 JTPXVCKCLBROOJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- MTOJDBAZGOYUOZ-UHFFFAOYSA-N 4-aminobenzenesulfonyl chloride Chemical compound NC1=CC=C(S(Cl)(=O)=O)C=C1 MTOJDBAZGOYUOZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 229950008545 sulfaclozine Drugs 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 230000002194 synthesizing effect Effects 0.000 claims description 13
- 239000012043 crude product Substances 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000003651 drinking water Substances 0.000 claims description 8
- 235000020188 drinking water Nutrition 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 230000008901 benefit Effects 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 10
- 238000001308 synthesis method Methods 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 8
- 239000012535 impurity Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 3
- 208000003495 Coccidiosis Diseases 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- 238000009874 alkali refining Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- CJTXZTONPFYCHZ-UHFFFAOYSA-N N1=CC=NC=C1.[Na] Chemical compound N1=CC=NC=C1.[Na] CJTXZTONPFYCHZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
测试项目 | 产率 | 产品纯度 |
单位 | % | % |
实施例1 | 99.1 | 99.3 |
实施例2 | 99.3 | 99.5 |
实施例3 | 99.6 | 99.6 |
实施例4 | 99.6 | 99.8 |
实施例5 | 99.7 | 99.9 |
对比例1 | 97.4 | 98.3 |
对比例2 | 82.5 | 96.3 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010230529.8A CN111217760B (zh) | 2020-03-27 | 2020-03-27 | 一种磺胺氯吡嗪钠的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010230529.8A CN111217760B (zh) | 2020-03-27 | 2020-03-27 | 一种磺胺氯吡嗪钠的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111217760A CN111217760A (zh) | 2020-06-02 |
CN111217760B true CN111217760B (zh) | 2021-11-26 |
Family
ID=70813389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010230529.8A Active CN111217760B (zh) | 2020-03-27 | 2020-03-27 | 一种磺胺氯吡嗪钠的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111217760B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113666876B (zh) * | 2021-07-05 | 2023-09-29 | 佛山市南海北沙制药有限公司 | 一种磺胺氯哒嗪的生产工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617489A (zh) * | 2012-03-21 | 2012-08-01 | 扬州天和药业有限公司 | 磺胺氯吡嗪钠的一种制备方法 |
CN104910081A (zh) * | 2014-03-15 | 2015-09-16 | 菏泽市方明制药有限公司 | 一种磺胺氯吡嗪钠的制备方法 |
CN104945338A (zh) * | 2015-06-23 | 2015-09-30 | 郑州福源动物药业有限公司 | 一种磺胺氯吡嗪钠的制备工艺 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10807983B2 (en) * | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
-
2020
- 2020-03-27 CN CN202010230529.8A patent/CN111217760B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617489A (zh) * | 2012-03-21 | 2012-08-01 | 扬州天和药业有限公司 | 磺胺氯吡嗪钠的一种制备方法 |
CN104910081A (zh) * | 2014-03-15 | 2015-09-16 | 菏泽市方明制药有限公司 | 一种磺胺氯吡嗪钠的制备方法 |
CN104945338A (zh) * | 2015-06-23 | 2015-09-30 | 郑州福源动物药业有限公司 | 一种磺胺氯吡嗪钠的制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN111217760A (zh) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110256506A (zh) | 一种制备氨基葡萄糖盐酸盐的方法 | |
CN112645864A (zh) | 一种克菌丹的制备方法 | |
CN111217760B (zh) | 一种磺胺氯吡嗪钠的合成方法 | |
CN102617489B (zh) | 磺胺氯吡嗪钠的一种制备方法 | |
CN110092747A (zh) | 一种含烟酸废水中烟酸回收、精制方法及废水处理方法 | |
CN107501260B (zh) | 一种Bcl-2抑制剂venetoclax以及中间体的制备方法 | |
CN109970543B (zh) | 阿昔洛韦缩合副产物与溶剂回收利用的方法 | |
CN108558776B (zh) | 2,4-二氨基-5-亚硝基-6-羟基嘧啶及鸟嘌呤的制备方法 | |
CN108017561A (zh) | 一种精制卡谷氨酸的方法 | |
CN108863822B (zh) | 一种精制盐酸异丙肾上腺素的方法 | |
CN102127081A (zh) | 一种腺嘌呤的制备方法 | |
CN111574416B (zh) | 一种以异硫脲盐与对甲基苯磺酸截短侧耳素酯制备泰妙菌素的方法 | |
CN110372528B (zh) | 一种缬氨酸的提纯方法 | |
CN111574412B (zh) | 一种制备牛磺酸的方法 | |
CN111548310B (zh) | 一种左西孟旦钠晶型及其制备方法 | |
CN106631850A (zh) | 一种对羟基苯甘氨酸合成的后处理工艺 | |
CN111303044A (zh) | 一种磺胺氯哒嗪钠的合成方法 | |
CN113402402B (zh) | 低浓度废液回收反式-对氨基环己醇的方法 | |
CN114478283B (zh) | 一种6-氨基己酸的制备方法 | |
CN103204783B (zh) | 一种d-赖氨酸盐酸盐的制备方法 | |
CN112500304B (zh) | 6-氨基己酸的制备方法 | |
CN113698323B (zh) | 一种减少酸析母液废水产出量的生产吐氏酸的方法 | |
CN107118246A (zh) | 一种新橙皮苷的合成工艺 | |
CN107417674B (zh) | 一种吡贝地尔的提纯方法 | |
US2724724A (en) | Preparation of concentrated solutions of alkylchlorophenoxyacetates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synthetic method of sulfaclopyrazine sodium Effective date of registration: 20230112 Granted publication date: 20211126 Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd. Registration number: Y2023430000003 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20211126 Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd. Registration number: Y2023430000003 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synthesis method of sulfamethoxazole sodium Granted publication date: 20211126 Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd. Registration number: Y2024980004057 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |